PR Newswire DENVER, Jan. 16, 2025 The American Board of Obesity Medicine (ABOM) recently announced that 1,801 physicians passed its board certification test administered in October 2024, bringing the number of physicians who are certified in ...
PR Newswire NEW YORK, Jan. 10, 2025 Novel siRNA Therapeutic Demonstrates Significant Fat Loss and Remarkable Lean Body Mass Preservation, and Promises Superior Adherence NEW YORK, Jan. 10, 2025 /PRNewswire/ - Canary Cure Therapeutics, a ...
PR Newswire HUNTINGTON, N.Y., Jan. 9, 2025 HUNTINGTON, N.Y., Jan. 9, 2025 /PRNewswire/ -- Sen-Jam Pharmaceutical, a leader in innovative anti-inflammatory care, today announced the submission of a new patent application that introduces a ...
PR Newswire SAN DIEGO, Jan. 8, 2025 13-Week Study to Evaluate the Safety and Efficacy of Oral VK2735 Dosed Once Daily SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage ...
PR Newswire NEW YORK, Dec. 26, 2024 Hoth Therapeutics Enters Exclusive Patent License Agreement with VA and Emory University Hoth Also Expands Its' Intellectual Property to Further Its' Market Opportunity for HT-001 NEW YORK, Dec. ...
PR Newswire SILVER SPRING, Md., Dec. 20, 2024 SILVER SPRING, Md., Dec. 20, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea ...
PR Newswire INDIANAPOLIS, Dec. 20, 2024 Averaging up to 20% of weight loss, adults taking Zepbound had at least 25 fewer breathing interruptions each hour as they slept Up to 50% of adults taking Zepbound no longer had symptoms ...
PR Newswire HONG KONG, Dec. 18, 2024 HONG KONG, Dec. 18, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces encouraging efficacy results from its study in diet-induced obese (DIO) mice combining ASC47, a ...
PR Newswire LEHI, Utah, Dec. 9, 2024 Study Demonstrates 16.6 % at day 7 to 29 % on terminal day 28 Weight Loss and Superior Efficacy Compared to peptide-based approved or clinical stage oral Obesity Drugs in the DIO Model LEHI, Utah, ...
PR Newswire LEHI, Utah, Dec. 5, 2024 LEHI, Utah, Dec. 5, 2024 /PRNewswire/ -- Halia Therapeutics, Inc. (Halia), a clinical-stage biopharmaceutical company at the forefront of developing innovative treatments for chronic inflammatory ...
GLP-1RA weight-loss drugs provide health benefits but also pose risks, including pancreatitis, kidney problems, and gastrointestinal issues.
Watch out! Muscle fat may increase the risk of heart disease and death, regardless of your body mass index (BMI).
Research reveals that while older adults tend to gain fat during the holidays, college students gain muscle, highlighting key differences in weight changes across life stages.
Revolutionizing obesity treatment: Once-monthly injections show promising results, offering a potential breakthrough in weight management.
Eli Lilly's Zepbound is set to dominate the global obesity market, offering new hope with its groundbreaking treatment for weight management.
Subscribe to our Free Newsletters!
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment.
Full Disclaimer
Advertise with us | Medindia Copyright | Privacy Policy | Terms of Use © All Rights Reserved 1997 - 2025
Careers